Websites
- Ambrx. Ambrx collaborates with Merck to design and develop biologic drug conjugates. www.ambrx.com/wt/page/pr_1340027257
- Xconomy. Merck bets $15M on Ambrx‘s ‘smart bomb‘ antibodies. www.xconomy.com/san-diego/2012/06/18/merck-bets-15m-on-ambrxs-smart-bomb-antibodies/
- Flowonix. Flowonix Medical Inc. secures $25 million in new capital. www.flowonix.com/press_releases/Flowonix_Financing.pdf
- PhaseBio raises $23M to continue clinical development of polymer-fused diabetes drugs. www.genengnews.com/gen-news-highlights/phasebio-raises-23m-to-continue-clinical-development-of-polymer-fused-diabetes-drugs/81246857/
- PR Newswire. Sangart raises additional $50M series G funding following interim safety analysis of phase 2b study Of MP4OX in severe trauma patients with hemorrhagic shock. www.prnewswire.com/news-releases/sangart-raises-additional-50m-series-g-funding-following-interim-safety-analysis-of-phase-2b-study-of-mp4ox-in-severe-trauma-patients-with-hemorrhagic-shock-153657505.html
- PR Newswire. Genzyme and Isis complete licensing of Mipomersen. www.prnewswire.com/news-releases/genzyme-and-isis-complete-licensing-of-mipomersen-57531517.html
- Yahoo Finance. Nektar says pain drug gets fast track US FDA status. http://finance.yahoo.com/news/nektar-says-pain-drug-gets-144054416.html
- Yahoo Finance. Nektar announces start of enrollment in Phase II study of NKTR-181, a novel opioid analgesic molecule, for treatment of chronic pain. http://finance.yahoo.com/news/nektar-announces-start-enrollment-phase-120000339.html
- Alkermes. Once-weekly Bydureon™ provided greater glucose control, weight loss and lower risk of hypoglycemia compared with once- or twice-daily levemir® in Type 2 diabetes. http://phx.corporate-ir.net/phoenix.zhtml?c=92211&p=irol-corporateNewsArticle&ID=1703915&highlight
- Alkermes. Invega® Sustenna® 3-month formulation of paliperidone palmitate enters Phase III clinical program for schizophrenia. http://phx.corporate-ir.net/phoenix.zhtml?c=92211&p=irol-corporateNewsArticle&ID=1704417&highlight
- Alkermes. Alkermes announces results from Phase II study of ALKS 37 for treatment of opioid-induced constipation. http://phx.corporate-ir.net/phoenix.zhtml?c=92211&p=irol-corporateNewsArticle&ID=1700902&highlight
- Alkermes. Alnylam announces top-line results of Phase IIb clinical trial of ALN-RSV01, an inhaled RNAi therapeutic for the treatment of respiratory syncytial virus (RSV) infection. http://phx.corporate-ir.net/phoenix.zhtml?c=148005&p=irol-newsArticle&ID=1700544&highlight
- Pharmaceutical Business Review. Alnylam completes enrollment in Phase I clinical trial and initiates Phase II clinical trial of ALN-TTR02, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of transthyretin-mediated amyloidosis (ATTR). http://clinicaltrials.pharmaceutical-business-review.com/news/alnylam-initiates-phase-ii-study-of-aln-ttr02-080612
- Celldex Therapeutics. Celldex‘s CDX-011 demonstrates high response rates in patients with metastatic breast cancer expressing elevated levels of GPNMB and in triple negative disease. http://ir.celldextherapeutics.com/phoenix.zhtml?c=93243&p=irol-newsArticle&ID=1699241&highlight
- American Society for Clinical Oncology. Emilia: T-DM1 demonstrates greater safety, efficacy for advanced HER2-positive breast cancer. http://chicago2012.asco.org/ASCODailyNews/LBA1.aspx
- Genentech. Genentech‘s targeted investigational breast cancer medicine, trastuzumab emtansine (T-DM1), reduced the risk of cancer worsening or death by 35 percent in pivotal Phase III trial. www.gene.com/gene/news/press-releases/display.do?method=detail&id=13948
- GlaxoSmithKline. GSK announces new 52-week data from Phase III study of once-weekly albiglutide in Type 2 diabetes. www.gsk.com/media/pressreleases/2012/2012-pressrelease-1125260.htm
- Bloomberg News. Makiko Kitamura. Glaxo diabetes drug data revealed amid hostile takeover. www.bloomberg.com/news/2012-05-24/glaxo-diabetes-drug-data-revealed-amid-hostile-takeover.html